Biopharma & Life Sciences
AN2 Therapeutics Executive Compensation (FY25)
ANTX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Eric Easom |
Free for 3 days · no card
See how AN2 Therapeutics’s pay stands against its peers
- AN2 Therapeutics's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
- Peer-group intelligence, custom peer reruns and governance screens
- Every other company we cover, with alerts when they file
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Data as of November 17, 2026Latest filing (DEF 14A): April 22, 2026
155 figures on this page, cited to the filing that reported them. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Eric Easom: $1,666,117 → $1,382,985 (17.0% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is AN2 Therapeutics' chief executive and what were they paid?
Eric Easom, President, Chief Executive Officer and Board Chair, received $1,382,985 in total compensation for fiscal 2025. Easom's total moved 17.0% lower from the $1,666,117 reported for fiscal 2024.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Eric Easom President, Chief Executive Officer and Director | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Paul Eckburg Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Lucy Day Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Eric Easom President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Lucy Day Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Paul Eckburg Former Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Josh Eizen Chief Legal Officer and Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Eric Easom President, Chief Executive Officer and Board Chair | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Josh Eizen Chief Legal Officer and Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Paul Eckburg Former Chief Medical Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Lucy Day Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Eric Easom President, Chief Executive Officer and Board Chair | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Josh Eizen Chief Legal Officer and Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Lucy Day Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Lucy Day | RSU | ◇ | — | — | — |
| RSU | ◇ | — | — | — | |
| RSU | ◇ | — | — | — | |
| Option | — | — | ◇ | April 29, 2031 | |
| Option | — | — | ◇ | December 8, 2030 | |
| Option | — | — | ◇ | September 23, 2030 | |
| Option | — | — | ◇ | January 22, 2030 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/25/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/14/2034 | |
| Option | ◇ | — | ◇ | 02/14/2033 | |
| Option | ◇ | — | ◇ | 05/11/2032 | |
| Josh Eizen | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 02/25/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/03/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/14/2034 | |
| Option | ◇ | — | ◇ | 02/14/2033 | |
| Option | ◇ | — | ◇ | 10/13/2032 | |
| Eric Easom | Option | — | — | ◇ | April 29, 2031 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/25/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/14/2034 | |
| Option | ◇ | — | ◇ | 02/22/2033 | |
| Option | ◇ | — | ◇ | 05/11/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Margaret FitzPatrick Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Stephanie Wong | ◇ | — | ◇ | — | — | — | ◇ |
Patricia Martin | ◇ | ◇ | ◇ | — | — | — | ◇ |
Joseph Zakrzewski | ◇ | — | ◇ | — | — | — | ◇ |
Rob Readnour, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Melvin Spigelman, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Gilbert Lynn Marks, M.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kabeer Aziz | ◇ | ◇ | ◇ | — | — | — | ◇ |
Eric Easom served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
What this page does not include
Everything above is a fact AN2 Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation ReportBoard and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance ReportRealizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
155 figures on this page, cited to the filing that reported them.
155 cited to the filing
Documents cited
- 0001193125-26-170314COMPENSATION OF NON-EMPLOYEE DIRECTORS
- 0000950170-25-052852
- 0000950170-24-049148
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “AN2 Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ANTX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about AN2 Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}